All In Biotech

Drug Trial Radar · NCT06106581

A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

A Randomized, Observer-blinded, Dose Response Phase 2 Trial to Assess the Safety and Immunogenicity of Two Different Dose Levels of a Live-attenuated Chikungunya Virus Vaccine (VLA1553) in Healthy Children Aged 1 to 11 Years

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Dec 18, 2023

Primary completion

Jul 31, 2024

Study completion Jul 2, 2025

Sponsor

Lead sponsor
Valneva Austria GmbHIndustry
Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 11 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control. At least 300 male and female healthy children aged 1 to 11 years will be enrolled and the overall distribution of participants will be 2:2:1 to the two VLA1553 dose groups (n=120 each) or control (n=60).

Conditions

  • Chikungunya Virus Infection

Interventions

  • VLA1553 full doseBiological

    Single intramuscular vaccination on Day 1 with VLA1553 full dose, a lyophilized live-attenuated Chikungunya vaccine candidate

  • VLA1553 half doseBiological

    Single intramuscular vaccination on Day 1 with VLA1553 half dose, a lyophilized live-attenuated Chikungunya vaccine candidate

  • ControlBiological

    Nimenrix

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Solicited Injection Site ReactionsTime frame: within 14 days post-vaccination
  2. Severity of Solicited Injection Site ReactionsTime frame: within 14 days post-vaccination
  3. Number of Participants With Solicited Systemic ReactionsTime frame: within 14 days post-vaccination
  4. Severity of Solicited Systemic ReactionsTime frame: within 14 days post-vaccination

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP

    Santo Domingo, Dominican Republic

  • Fundacion Dominicana de Perinatologia Fundacion Probebe

    Santo Domingo, Gazcue, Dominican Republic

  • Inversiones en Investigacion Medica INVERIME

    Tegucigalpa, Honduras

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.